Effet of immune modulation in relapsed peripheral T-cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Mamez; Levy, V; Chevallier, P; Blaise, D; Vigouroux, S; Xhaard, A; Fegueux, N; Contentin, N; BEGUIN, Yves; Ifrah, N; Bulabois, CE; Suarez, F; Yakoub-Agha, I; Turlure, P; Deconink, E; Lamy, T; Cahn, J-Y; Huynh, A; Maury, S; Fornecker, L-M; Ouzegdouh, M; Bay, J-O; Guillerm, G; Maillard, N; Michallet, M; Malfuson, J-V; Bourhis, J-H; Rialland, F; Oumedaly, R; Jubert, C; Leblond, V; Boubaya, M; Mohty, M; Nguyen, S

doi:10.1038/bmt.2015.280

Article (Scientific journals)

Effet of immune modulation in relapsed peripheral T-cell lymphomas after allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Mamez; Levy, V; Chevallier, P et al.

2016 • In Bone Marrow Transplantation, 51, p. 358-364

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/205987

DOI
10.1038/bmt.2015.280

PubMed
26595076

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

364.pdf

Publisher postprint (440.56 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Abstract :

[en] Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with nonimmunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68–48.21), P = 0.0009) and skin relapse (odds ratio: 4.15 (1.04–16.50), P = 0.043) were associated with a better response to treatment at relapse. In a time-dependent analysis, the only factor predictive of OS was the time from transplantation to relapse (hazards ratio: 0.33 (0.17–0.640), P = 0.0009). This large series provides encouraging evidence of a true GvL effect in this disease.

Disciplines :

Hematology

Author, co-author :

Mamez

Levy, V

Chevallier, P

Blaise, D

Vigouroux, S

Xhaard, A

Fegueux, N

Contentin, N

BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique

Ifrah, N

More authors (24 more)

Language :

English

Title :

Publication date :

2016

Journal title :

Bone Marrow Transplantation

ISSN :

0268-3369

eISSN :

1476-5365

Publisher :

Nature Publishing Group, London, United Kingdom

Volume :

Pages :

358-364

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 26 January 2017

Statistics

Number of views

106 (0 by ULiège)

Number of downloads

103 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Abouyabis AN, Shenoy PJ, Sinha R, Flowers CR, Lechowicz MJ. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011; 2011: 623924.
Reimer P, Rüdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009; 27: 106-113.
Kyriakou C, Canals C, Finke J, Kobbe G, Harousseau J-L, Kolb H-J et al. Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009; 27: 3951-3958.
Gouill SL, Milpied N, Buzyn A, Latour RPD, Vernant J-P, Mohty M et al. Graft-versuslymphoma effect for aggressive t-cell lymphomas in adults: a study by the Société Française De Greffe De Mo?lle et De Thérapie Cellulaire. J Clin Oncol 2008; 26: 2264-2271.
Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 2012; 26: 520-526.
Goldberg JD, Chou JF, Horwitz S, Teruya-Feldstein J, Barker JN, Boulad F et al. Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant. Leuk Lymphoma 2012; 53: 1124-1129.
Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28: 4492-4499.
Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC et al. A large singlecenter experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol 2011; 22: 1608-1613.
Zain J, Palmer JM, Delioukina M, Thomas S, Tsai N-C, Nademanee A et al. Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leuk Lymphoma 2011; 52: 1463-1473.
Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T et al. Upfront allogeneic-stem cell transplantation for patients with non-localized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center. Ann Oncol 2014; 26: 386-392.
Robles M, Vigouroux S, Tabrizi R, Bouabdallah K, Dilhuydy M-S, Parrens M et al. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response. Bone Marrow Transplant 2013; 48: 1484-1485.
Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M et al. Graft-versuslymphoma effect in relapsed peripheral T-cell non-Hodgkin?s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004; 22: 2172-2176.
Itonaga H, Tsushima H, Taguchi J, Fukushima T, Taniguchi H, Sato S et al. Treatment of relapsed adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Blood 2013; 121: 219-225.
Kanakry JA, Kasamon YL, Gocke CD, Tsai H-L, Davis-Sproul J, Ghosh N et al. Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant 2013; 19: 602-606.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
Mamez AC, Souchet L, Roos-Weil D, Uzunov M, Brun AL, Algrin C et al. Graftversus-T-cell lymphoma effect: a sustained CR after tapering immunosuppressive drugs in a patient with angioimmunoblastic T-cell lymphoma in relapse after allogeneic transplantation. Bone Marrow Transplant 2014; 50: 304-306.
Molina A, Zain J, Arber DA, Angelopolou M, O?Donnell M, Murata-Collins J et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 2005; 23: 6163-6171.
Yuan L, Sun L, Bo J, Zhou Y, Li H, Yu L et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Ann Transplant 2011; 16: 135-138.
Kako S, Izutsu K, Oshima K, Sato H, Kanda Y, Motokura T et al. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007; 82: 937-939.
Chakraverty R, Mackinnon S. Allogeneic transplantation for lymphoma. J Clin Oncol 2011; 29: 1855-1863.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group. J Clin Oncol 2003; 21: 2747-2753.
Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O?Connor OA et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 2014; 123: 3095-3100.